NEW YORK CITY (dpa-AFX) - Drugmaker Pfizer Inc. (PFE) announced on Wednesday that it has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics for three preclinical in vivo CAR-T programs targeting autoimmune diseases.
Under the agreement, Pfizer will obtain exclusive rights outside Greater China to develop, manufacture and commercialize the programs, along with rights to use Starna's in vivo CAR-T technology in inflammation and immunology and oncology.
Starna will receive an upfront payment of $330 million and is eligible for upto $2.3 billion in development and commercial milestone payments, plus royalties on net sales of approved products.
Pfizer said it would lead clinical development outside Greater China and manufacture finished drug products for initial clinical trials in the United States.
The company also received options to license compounds developed under a separate research collaboration and to expand the agreement to include Greater China.
Shares of Pfizer fell 0.70% to $28.26 in premarket trading after ending Tuesday's session down 1.35%.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News



